| Literature DB >> 33798034 |
Brendan Saloner1, Barbara Andraka Christou2,3, Adam J Gordon4,5,6, Bradley D Stein7.
Abstract
Buprenorphine is one of the gold standard medication treatments for opioid use disorder (OUD), with proven effectiveness in preventing overdose, increasing abstinence, and improving quality of life. In the United States, buprenorphine can be legally prescribed and administered in office-based settings from clinicians who are specially credentialed to provide that care under the X-waiver. We believe the X-waiver will ultimately be repealed, but there is a need for a variety of strategies to create a new treatment system after the X-waiver. Building a new tier of treatment capacity will require educational outreach, systems strategies, and enhanced payments.Entities:
Keywords: Buprenorphine; DATA 2000; access to care; policy; quality of care
Mesh:
Substances:
Year: 2021 PMID: 33798034 PMCID: PMC8667660 DOI: 10.1080/08897077.2021.1903659
Source DB: PubMed Journal: Subst Abus ISSN: 0889-7077 Impact factor: 3.716